SG78239A1 - Angiogenesis inhibitory antibodies - Google Patents

Angiogenesis inhibitory antibodies

Info

Publication number
SG78239A1
SG78239A1 SG1996000859A SG1996000859A SG78239A1 SG 78239 A1 SG78239 A1 SG 78239A1 SG 1996000859 A SG1996000859 A SG 1996000859A SG 1996000859 A SG1996000859 A SG 1996000859A SG 78239 A1 SG78239 A1 SG 78239A1
Authority
SG
Singapore
Prior art keywords
pct
endothelial cells
angiogenesis
sec
inhibitory antibodies
Prior art date
Application number
SG1996000859A
Other languages
English (en)
Inventor
Christopher Richard Parish
Original Assignee
Univ Australian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3776506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG78239(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Australian filed Critical Univ Australian
Publication of SG78239A1 publication Critical patent/SG78239A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
SG1996000859A 1992-10-29 1993-10-29 Angiogenesis inhibitory antibodies SG78239A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPL557392 1992-10-29

Publications (1)

Publication Number Publication Date
SG78239A1 true SG78239A1 (en) 2001-02-20

Family

ID=3776506

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996000859A SG78239A1 (en) 1992-10-29 1993-10-29 Angiogenesis inhibitory antibodies

Country Status (9)

Country Link
US (2) US5677181A (de)
EP (1) EP0669988B2 (de)
JP (1) JP3490443B2 (de)
AT (1) ATE250138T1 (de)
AU (1) AU673865B2 (de)
CA (1) CA2148244A1 (de)
DE (1) DE69333209T2 (de)
SG (1) SG78239A1 (de)
WO (1) WO1994010331A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
JP3490443B2 (ja) * 1992-10-29 2004-01-26 ジ・オーストラリアン・ナショナル・ユニバーシティ 血管形成阻害性抗体
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
WO2000002584A2 (en) 1998-07-13 2000-01-20 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
CA2331789C (en) 1998-07-13 2013-09-10 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US6887468B1 (en) 1999-04-28 2005-05-03 Board Of Regents, The University Of Texas System Antibody kits for selectively inhibiting VEGF
US7261881B1 (en) 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
US6824773B2 (en) * 1999-12-20 2004-11-30 Immunex Corporation TWEAK receptor
US6727192B2 (en) * 2001-03-01 2004-04-27 Micron Technology, Inc. Methods of metal doping a chalcogenide material
US20030139374A1 (en) * 2001-09-27 2003-07-24 Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. Combined methods for tumor vasculature coagulation and treatment
EP1487492A4 (de) * 2002-03-04 2008-10-01 Medimmune Inc Prävention oder behandlung von krebs mit integrin alphavbeta3 antagonisten in kombination mit anderen mitteln
US20050084489A1 (en) * 2002-03-04 2005-04-21 Wilder Ronald L. Methods of preventing or treating disorders by administering and integrin alphanubeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
AU2003272449A1 (en) * 2002-09-16 2004-04-30 Exelixis, Inc. MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
US7285268B2 (en) 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US20040176272A1 (en) * 2003-01-30 2004-09-09 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
EP1625165A2 (de) * 2003-04-03 2006-02-15 Protein Design Labs, Inc. Integrin alpha5beta1 inhibitoren und deren verwendung zur kontrolle der gewebe-granulation
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US8491883B2 (en) 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US7875272B2 (en) * 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
AU2005322060B2 (en) 2003-06-27 2011-11-17 Ethicon Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US8703121B2 (en) 2003-06-27 2014-04-22 DePuy Synthes Products, LLC Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
EP1755659B1 (de) * 2004-03-24 2011-11-02 Abbott Biotherapeutics Corp. Verwendung von anti-alpha5beta1-antikörpern zur hemmung der krebszellproliferation
JP4864900B2 (ja) 2004-11-18 2012-02-01 イムクローン・リミテッド・ライアビリティ・カンパニー 血管内皮成長因子受容体−ｉに対する抗体
IL165365A0 (en) 2004-11-24 2006-01-15 Q Core Ltd Finger-type peristaltic pump
AU2005322133B2 (en) 2004-12-23 2011-06-30 Ethicon Incorporated Treatment of Parkinson's disease and related disorders using postpartum derived cells
PL1971681T3 (pl) 2005-12-16 2018-01-31 Depuy Synthes Products Inc Kompozycje oraz sposoby do hamowania niepożądanej odpowiedzi immunologicznej w przypadku transplantacji z brakiem zgodności tkankowej
JP5179376B2 (ja) 2005-12-19 2013-04-10 エシコン・インコーポレイテッド ローラーボトルでの分娩後取り出し細胞の体外増殖
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
JP2010534685A (ja) * 2007-07-27 2010-11-11 ファセット バイオテック コーポレイション チロシンキナーゼ阻害剤およびインテグリンα５β１（ＣＤ４９Ｅ）に対する抗体を含む薬学的な組み合わせ
BRPI0818183A2 (pt) 2007-10-05 2019-07-16 Ethicon Inc reparo e regeneração do tecido renal usando células derivadas do tecido do cordão umbilical humano
US8236538B2 (en) 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
ES2665883T3 (es) 2008-12-19 2018-04-30 DePuy Synthes Products, Inc. Tratamiento de enfermedades y trastornos pulmonares y pulmonares
WO2010111663A1 (en) 2009-03-26 2010-09-30 Ethicon, Inc. Human umbilical cord tissue cells as therapy for alzheimer' s disease
RU2636220C2 (ru) 2011-12-23 2017-11-21 Депуи Синтез Продактс, Инк. Обнаружение клеток, полученных из ткани пуповины человека

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721672A (en) * 1985-08-28 1988-01-26 President And Fellows Of Harvard College CDNA and gene for human angiogenin (angiogenesis factor) and methods of expression
US5512660A (en) * 1987-05-04 1996-04-30 Dana Farber Cancer Institute, Inc. Purified ICAM-2 and fragment thereof
JPH02502156A (ja) † 1987-11-19 1990-07-19 スクリップス　クリニック　アンド　リサーチ　ファウンデーション 内皮細胞のｒｇｄ指向粘着レセプターに対するモノクローナル抗体
IL94055A (en) * 1989-04-10 1995-11-27 Oncogen Oncostatin M Container Pharmaceuticals to Change Tissue Immunogenicity and Improve Implant Absorption
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
IT1239065B (it) * 1990-05-14 1993-09-20 Fidia Spa Anticorpo monoclonale che inibisce l'azione biologica del fattore piastrinico 4
EP0505749A3 (en) * 1991-02-26 1993-06-23 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to activated endothelial cells and their therapeutic and diagnostic use
JP3490443B2 (ja) * 1992-10-29 2004-01-26 ジ・オーストラリアン・ナショナル・ユニバーシティ 血管形成阻害性抗体

Also Published As

Publication number Publication date
DE69333209T2 (de) 2004-07-01
AU5366194A (en) 1994-05-24
WO1994010331A1 (en) 1994-05-11
US5874081A (en) 1999-02-23
JP3490443B2 (ja) 2004-01-26
JPH08502409A (ja) 1996-03-19
AU673865B2 (en) 1996-11-28
EP0669988B2 (de) 2009-07-08
DE69333209D1 (de) 2003-10-23
US5677181A (en) 1997-10-14
EP0669988A1 (de) 1995-09-06
EP0669988A4 (de) 1996-07-31
EP0669988B1 (de) 2003-09-17
CA2148244A1 (en) 1994-05-11
ATE250138T1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
SG78239A1 (en) Angiogenesis inhibitory antibodies
Jiang et al. Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets.
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
NO955029L (no) Intravaginalt avleveringssystem
DK151687A (da) Aprotinin-homologe fremstillet ud fra en rekombinant vaert, fremgangsmaade, ekspressionsvektor og rekombinant vaert derfor og farmaceutisk anvendelse deraf
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
DK0592521T3 (da) Marv-afledte humane mesenchymal-stamceller og monoklonale antistoffer specifikke for nævnte celler
Reyes et al. Collagenase production at the border of granulation tissue in a healing wound: macrophage and mesenchymal collagenase production in vivo
DE68918944D1 (de) Künstliche rezeptor-analoge.
NZ290422A (en) Pyridyl or pyrimidinyl substituted thiopyridine derivatives and medicaments
GEP20002257B (en) Method for Reducing Fibrin Accumulation Speed, Prophylactics of Thrombus Complications and Treatment of Blood Vessels Diseases, Medicinal Composition and Medicinal Species
AU5810498A (en) Method and constructs for inhibiting protein expression in bacteria
ES2057572T3 (es) Agentes de reconocimiento.
GB2270626B (en) Use of lectins for treatment of skin diseases
DE59801127D1 (de) Verwendung eines extraktes von alchemilla vulgaris
MX9700042A (es) Aislados de bacillus thurigiensis activo contra cucarachas.
NO951277L (no) Desulfatohirudin med höy molekylvekt
PL323195A1 (en) Alpha unit of human integrin beta 2
AU2002366739A8 (en) Apoptotically active peptides
ATE279521T1 (de) Regulierende nukleinsaeuresequenzen und verwendungen
ITRM930280A0 (it) Contenitore per imballaggio di biancheria d'arredamento, intima e abbigliamento.
UA18224A (uk) Спосіб лікуваhhя дерматозів
IT1288184B1 (it) Procedimento per l'accorciamento del tempo di chiusura e dispositivo per l'attuazione del procedimento.
Remport Isothermal Growth of Austenite of Unalloyed Steels
HU9200336D0 (en) 2,4- and 2,5-bis-tetrazolyl-piridine-derivatives, process for their production and medical preparations containing them